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Experimental studies suggest that red wine has cardiovascular 
protective effects ‘beyond the alcohol’. Epidemiological, clinical 
and laboratory studies provide evidence for benefit from 
moderate alcohol consumption in cardiovascular health.1 Alcohol 
consumption, from whatever source, appears to have a J-shaped 
curve, whereby a modest intake is beneficial and either no intake 
or increased intake is harmful.2 The J-shaped mortality curve 
might in part be explained by less myocardial infarction3 and fewer 
incidences of heart failure.4 The maximal protective effect occurs 
between half and one drink per day.5 In contrast, the risk of cancers 
tends to increase with the amount of ethanol consumed, and it is not 
clear whether a threshold exists below which this side-effect is not 
observed.6 Therefore, the consumption of alcohol should be kept low 
to achieve cardioprotective benefits without enhancing the alcohol-
related side-effects on the liver.
Red wine polyphenol extracts have cardioprotective properties 
against ischaemia/reperfusion7 and these effects have mainly been 
attributed to the polyphenol resveratrol – a potent antioxidant and 
activator of prosurvival pathways.8 However, the proportion of the 
cardioprotective effect attributable to the alcohol or the polyphenols 
in red wine is still unclear. 
We aimed to compare the antioxidant and cardioprotective 
properties of a French red wine (cabernet sauvignon, 12% alcohol by 
volume: wine 12%) with the same wine treated for partial removal of 
alcohol content (6% alcohol by volume: wine 6%).
Methods
French red, rosé and white wines were used in this study. To achieve 
their corresponding low-alcohol product, alcohol was removed 
by the lirisation process9 from 12% to 6% alcohol by volume, 
without any other alteration of the original composition (http://www.
michaelpaetzold.com).9
The antioxidant properties of the wines were evaluated in vitro 
using the oxygen radical absorbance capacity (ORAC) assay with 
fluorescein.10 Values were measured as mmol/l Trolox equivalents 
(TE). 
The drinking water used for the male Long Evans control rats 
(CTL) group was supplemented by red wine (French cabernet 
sauvignon: wine 12% group), with its corresponding low-alcohol 
product (wine 6% group) or with the alcohol extracted from the wine 
(6% or 12% volume/volume). The different drinking solutions were 
prepared daily by adding one part of red wine or alcohol solution to 
seven parts of drinking water (equivalent of 2 glasses per day relative 
to body weight).11 After 10 days of treatment, rats were anaesthetised 
with sodium pentobarbitone (60 mg/kg, intraperitoneal) and received 
heparin (200 IU intravenously (IV)). 
Hearts were excised and perfused on a Langendorff perfusion 
system.12 Cardiac parameters were monitored continuously and 
included heart rate (HR), left ventricular developed pressure (LVDP; 
the difference between left ventricular end systolic pressure and 
left ventricular end diastolic pressure) and the coronary flow. Rate 
pressure product (RPP) was calculated as the HR x LVDP for a 
specific time point. All rat hearts were equilibrated for 30 minutes 
and subjected to 30 minutes of global ischaemia (37oC) followed 
by 30 minutes of reperfusion (I/R). The study was approved by the 
Animal Research Ethic Committee, University of Cape Town. 
Data were expressed as mean values ± standard error of the mean 
and were analysed by performing multiple group comparisons using 
one-way analysis of variance (ANOVA) followed by Tukey post hoc 
test (Graph Pad Instat). A value of p<0.05 was considered to be 
statistically significant.
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benefits cardiovascular health, because of the alcoholic content or 
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French red wine (cabernet sauvignon, 12% alcohol by volume) 
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cardioprotective effect of 12% v. 6% wine, the drinking water of rats 
used for controls was supplemented with red wine (12% or 6%). After 
10 days, hearts were isolated on a Langendorff system and subjected to 
30 minutes of global ischaemia plus 30 minutes of reperfusion (I/R). 
Results. No differences in antioxidant capacity were observed 
between wine of 12% and 6% alcohol content (n=8 per group). 
Control hearts subjected to I/R presented a rate pressure product 
(heart rate x left ventricular developed pressure, expressed as a 
percentage of baseline value) of 16±4% (mean±standard error). 
Pretreatment with wine 12% or 6% improved the rate pressure 
product to 40±6% and 43±6%, respectively (p<0.05 v. control).
Conclusion. Our findings suggest that the reduction of alcohol 
content from 12% to 6% in wine did not alter its antioxidant and 
cardioprotective properties. Moderate and regular consumption of 
lower alcohol content wines may confer beneficial effects without 
the risks associated with traditional wines of higher alcohol content.
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Results
The in vitro antioxidant properties of red wine were much higher 
than those of rosé or white wine (30.6±0.9, 6.3±0.1 and 4.0±0.1 
mmol/l Trolox equivalent, respectively, p<0.05 v. white wine) (Fig. 
1). These results conform to previous reports. The reduction of 
the alcohol content to 6% in the 3 types of wine did not affect 
the antioxidant properties of the wine (30.6±0.9 mmol/l Trolox 
equivalent for the red wine 12% and 30.4±0.9 for the wine 6% (not 
significant (NS); n=6 per group). 
Pretreatment with wine (12% or 6%) or alcohol (12% or 6%) did not 
affect the functional parameters of the isolated rat heart prior to the 
ischaemic insult. After I/R, large alterations of haemodynamic function 
were observed in all groups. For the ischaemic control group, the end 
of the reperfusion was marked by a dramatic decrease of LVDP, HR 
and coronary flow compared with the pre-ischaemic values (Table 1). 
Pretreatment with wine 12% or 6% improved LVDP function after 
reperfusion (Table 1) compared with control hearts (p<0.05). No 
difference was observed in the haemodynamic parameters between 
wine 12% and wine 6%. Control hearts subjected to I/R presented a 
RPP (expressed as a percentage of baseline value) of 19±1% (Fig. 2). 
Pretreatment with wine 12% or 6% improved the RPP to 37±5% and 
37±4%, respectively (p<0.05 v. control). Pretreatment with alcohol 
12% or 6% for 10 days did not improve the LVDP, HR and coronary 
flow after 30 minutes of reperfusion compared with control hearts 
(Table 1; NS). Similarly, the RPP did not improve with pretreatment 
of alcohol 12% or 6% compared with the control group (Fig. 2, NS).
Discussion
Our data provide the first evidence that chronic and moderate 
administration of red wine to rats for 10 days is protective against 
an I/R insult. Most importantly, we show that the reduction of 
alcohol content in wine from 12% to 6% does not alter its antioxidant 
properties in vitro or its cardioprotective effect against I/R injury.
Low-alcohol wine and antioxidant properties
Our work clearly demonstrates that lirisation does not affect the 
antioxidant properties of the wine. Additional studies (data not 
shown) demonstrate that a complete removal of alcohol content does 
not alter the antioxidant properties of the wine, suggesting that these 
properties can be attributed mainly to components of the wine other 
than alcohol. Furthermore, our data show that the antioxidant capacity 
of red wine is superior to that of white wine. Other antioxidants 
including the polyphenols resveratrol and anthocyanins are found 
mainly in red wine.7 Further work will examine the contribution of 
each component in the antioxidant repertoire of wines.  
Low-alcohol wine and cardioprotective effect
Low-dose ethanol drinking improves recovery of cardiac function 
and limits infarct size following an ischaemic insult.8 Non-alcoholic 
extracts of red wine and resveratrol also reduce infarct size.13 
The fraction rich in polymeric proanthocyanidins separated from 
Argentinian red wine exerts the most powerful cardioprotective 
effect against ischaemia.14 None of these earlier studies, however, 
explored the cardioprotective effect of the wine against ischaemia 
in its entirety. The present study demonstrates that chronic and 
moderate administration of red wine with an alcohol content of 12% 
protected the rats against an ischaemic insult. Halving the alcohol 
Fig. 1. Comparison of the antioxidant properties of white, rosé and red wines 
(12% alcohol volume/volume) compared with the same wine after alcohol 
removal to a final concentration of 6%. *p<0.05 compared with white wine 
12%; #p<0.05 compared with white wine 6%; n=6 per group. ORAC = 
oxygen radical absorbance capacity.
Fig. 2. Rate pressure product (RPP): heart rate x left ventricular developed 
pressure expressed as a percentage of baseline in isolated rat heart subjected 
to an ischaemia/reperfusion insult.*p<0.05 v. control; n=6 per group.
Table 1. Haemodynamic parameters of perfused rat hearts
Pre-ischaemic
Reperfusion
5 min
Reperfusion 
30 min
LVDP (mmHg)
Control 87±1 16±2 23±3
Wine 6% 87±2 27±5* 36±3*
Wine 12% 88±3 26±3* 38±3*
Alcohol 6% 87±5 12±2 26±2
Alcohol 12% 87±6 10±4 17±2
Heart rate (bts/min)
Control 340±17 192±32 227±20
Wine 6% 307±13 260±34 270±18
Wine 12% 300±9 250±37 253±29
Alcohol 6% 304±10 228±27 260±29
Alcohol 12% 328±15 232±66 286±36
Flow (ml/min)
Control 13.0±1.1 7.3±0.4 5.5±0.3
Wine 6% 13.5±1.0 9.6±0.7 5.6±0.2
Wine 12% 11.8±1.4 10.0±0.9 6.7±0.4
Alcohol 6% 11.6±0.2 9.8±0.6 6.6±0.7
Alcohol 12% 10.4±0.6 9.2±0.5 7.0±0.6
Parameters measured prior to ischaemia (pre-ischaemic), after 5 and 30 min of reperfusion. 
Values are mean ± standard error of mean (n=6). LVDP=left ventricular developed pressure.
*p<0.05 v. control.
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content did not alter this protective effect, suggesting that the alcohol 
fraction may play a minor role in cardioprotection relative to the 
polyphenols. Pretreatment of our animals with alcohol 6% or 12% 
alone, was not enough to protect the heart against an I/R insult. 
The cardioprotective effect of red wine is likely to be attributed to 
other antioxidants such as resveratrol that confer anti-ischaemic 
effects via the activation of prosurvival pathways, including the 
survivor activating factor enhancement (SAFE) pathway.15 It will be 
of interest to elucidate whether these other protective mechanisms 
still remain active when the alcohol content has been reduced to 6% 
and additional experiments, with complete removal of all alcohol 
content, will be required to establish if polyphenols alone can provide 
cardioprotection. 
In conclusion, our findings suggest that the reduction of 
alcohol content to 6% in the wine did not alter its antioxidant and 
cardioprotective properties. Moderate and regular consumption of 
wines, with a lower content of alcohol than traditional wines, may 
confer a beneficial cardioprotective effect without the risks associated 
with higher alcohol consumption.  
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